ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACADIA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$19.80+0.68 (+3.56%)
Close on Oct 19, 2026
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- Dividend yield
- –
Acadia Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $3.41B | $197.05M |
| Enterprise Value | $2.46B | $106.56M |
| PE Ratio | 8.96 | 20.52 |
| PS Ratio | 3.00 | 3.93 |
| PB Ratio | 2.61 | 2.14 |
| P/TBV Ratio | 2.84 | 2.46 |
| P/FCF Ratio | 23.43 | 18.25 |
| P/OCF Ratio | 21.28 | 13.78 |
Enterprise value
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.16 | 2.69 |
| EV / EBITDA | 28.43 | 14.86 |
| EV / EBIT | 28.43 | 19.00 |
| EV / FCF | 16.86 | 21.02 |
Income (trailing twelve months)
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $1.14B | $57.94M |
| Gross Profit | $1.04B | $90.47M |
| Operating Income | $86.37M | -$21.44M |
| Pretax Income | $121.37M | -$14.45M |
| Net Income | $380.48M | -$22.46M |
| EBITDA | $86.37M | -$16.91M |
| EPS (Diluted) | $2.21 | -$0.83 |
Margins
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 91.1% | 52.3% |
| Operating Margin | 7.59% | -44.5% |
| Pretax Margin | 10.7% | -13.0% |
| Profit Margin | 33.4% | -39.2% |
| EBITDA Margin | 7.59% | -31.3% |
| FCF Margin | 12.8% | -8.85% |
Returns
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 35.7% | -53.1% |
| Return on Assets (ROA) | 25.6% | -41.0% |
| Return on Invested Capital (ROIC) | 42.1% | -32.0% |
| Return on Capital Employed (ROCE) | 6.25% | -37.8% |
Growth
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.8% | 6.01% |
| Net Income Growth (YoY) | 71.3% | -37.7% |
| EPS Growth (YoY) | 66.2% | -29.2% |
| FCF Growth (YoY) | -22.2% | 2.34% |
| Revenue Growth (3Y CAGR) | 27.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 19.4% | 6.42% |
Balance sheet
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $956.47M | $62.42M |
| Net Cash (Debt) | $956.47M | $15.68M |
| Net Cash Per Share | $5.55 | $0.65 |
| Equity (Book Value) | $1.31B | $48.79M |
| Book Value Per Share | $7.58 | $1.36 |
| Tangible Book Value | $1.20B | $23.06M |
| Working Capital | $863.11M | $75.77M |
Financial position
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.39 | 3.30 |
| Quick Ratio | 3.06 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $160.32M | -$12.35M |
| Capital Expenditures | -$14.69M | -$1.06M |
| Free Cash Flow | $145.63M | -$20.28M |
| FCF Per Share | $0.85 | -$0.41 |
Efficiency
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.77 | 0.38 |
| Inventory Turnover | 0.92 | 2.67 |
| Revenue Per Employee | $1.43M | $398.96K |
| Profits Per Employee | $476.80K | -$732.08K |
| Employee Count | 798 | 73 |
Dividends and yields
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 11.2% | -21.2% |
| FCF Yield | 4.27% | -7.64% |
| Buyback Yield | -1.37% | -0.58% |
| Shareholder Yield | -1.37% | 0.00% |
Shares
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 172,306,000 | 59,128,900 |
| Shares Change (YoY) | 2.81% | 11.1% |
| Shares Change (QoQ) | 0.61% | 0.54% |
| Float | 124,445,000 | 48,744,500 |
| Shares Held by Insiders | 27.8% | 11.8% |
| Shares Held by Institutions | 97.9% | 59.4% |
Taxes
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$259.12M | $91.50K |
| Effective Tax Rate | -213.5% | 20.6% |
Scores
| Measure | Acadia Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $19.42 | $17.36 |
| Graham Upside | -1.93% | -45.5% |
| Altman Z-Score | 4.67 | 0.10 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Acadia Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.